What is the treatment for high-risk Ta, T1, and carcinoma in situ (CIS) bladder cancer?

Updated: Feb 23, 2021
  • Author: Kara N Babaian, MD, FACS; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
  • Print
Answer

Intravesical instillation of BCG is used in the treatment of high-risk Ta, T1, and CIS urothelial carcinoma of the bladder. Immunotherapy with BCG is the most effective intravesical therapy for CIS and T1 tumors. It is less effective in reducing the 5-year recurrence rate for low-grade and low-stage urothelial carcinoma (see Table 2, below).

Table 2. Recurrence and Progression Rates at 5 Years for Ta, T1, and CIS TCC of the Bladder Treated With BCG (Open Table in a new window)

Stage

Recurrence, %

Progression, %

Ta

55

11

T1

61

31

CIS

45

23

G1

61

2-4

G2

56

5-7

G3

50-70

30-40


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!